weight gain on tirzepatide outperformed semaglutide weight-loss drug results in real world patients, study shows How Tirzepatide May Help Manage

PDC is calculated as (number of days covered) / (total days in the time period) Cohorts and Time Horizons The second phase of analysis extends and refines the original analysis by separating cohorts by primary indication: Diabetes cohort: Individuals with a diabetes indication and GLP-1 use primarily for glycemic control Weight loss cohort: Individuals using GLP-1s for obesity or weight management without a diabetes indication Extending observation periods 30-month analysis window for the diabetes cohort 18-month analysis window for the weight loss cohort This approach allows us to evaluate whether the cost and clinical trends seen in the first white paper persist over a longer timeframe and whether they hold consistently across key sub populations

We collaborate only with recognized manufacturers that operate under industry standards and regulatory compliance frameworks

Severe kidney or liver problems

This medicine may increase the risk of these tumors

Call us at (206) 324-1120 to schedule your free consultation or book your appointment online.